<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Breast Cancer Res Treat</journal-id><journal-id journal-id-type="iso-abbrev">Breast Cancer Res Treat</journal-id><journal-title-group><journal-title>Breast Cancer Research and Treatment</journal-title></journal-title-group><issn pub-type="ppub">0167-6806</issn><issn pub-type="epub">1573-7217</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39581892</article-id><article-id pub-id-type="pmc">PMC11785676</article-id>
<article-id pub-id-type="publisher-id">7524</article-id><article-id pub-id-type="doi">10.1007/s10549-024-07524-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Real-world quality-of-life of patients with HR+/HER2&#x02212;&#x02009;advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Rocque</surname><given-names>Gabrielle B.</given-names></name><address><email>grocque@uabmc.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Blum</surname><given-names>Joanne L.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ji</surname><given-names>Yan</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Pluard</surname><given-names>Timothy</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Migas</surname><given-names>John</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Lakhanpal</surname><given-names>Shailendra</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Jepsen</surname><given-names>Erin</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Gauthier</surname><given-names>Eric</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Yao</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Montelongo</surname><given-names>Monica Z.</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Cappelleri</surname><given-names>Joseph C.</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Karuturi</surname><given-names>Meghan S.</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Tripathy</surname><given-names>Debu</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/008s83205</institution-id><institution-id institution-id-type="GRID">grid.265892.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 0634 4187</institution-id><institution>University of Alabama at Birmingham, </institution></institution-wrap>Birmingham, AL USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02ketev28</institution-id><institution-id institution-id-type="GRID">grid.477898.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0428 2340</institution-id><institution>Baylor-Sammons Cancer Center, Texas Oncology, US Oncology, </institution></institution-wrap>Dallas, TX USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03s9ada67</institution-id><institution-id institution-id-type="GRID">grid.280625.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0461 4886</institution-id><institution>Health Partners Institute, </institution></institution-wrap>St. Paul, MN USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0127qs140</institution-id><institution-id institution-id-type="GRID">grid.419820.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 0383 1037</institution-id><institution>Saint Luke&#x02019;s Cancer Institute, </institution></institution-wrap>Kansas City, MO USA </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05x3ned27</institution-id><institution-id institution-id-type="GRID">grid.477503.2</institution-id><institution>Mid-Illinois Hematology &#x00026;, </institution><institution>Oncology Associates Ltd, </institution></institution-wrap>Normal, IL USA </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/000crk757</institution-id><institution-id institution-id-type="GRID">grid.492939.c</institution-id><institution>Saint Vincent&#x02019;s Birmingham, </institution></institution-wrap>Birmingham, AL USA </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04nv2wh79</institution-id><institution-id institution-id-type="GRID">grid.462729.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 0486 157X</institution-id><institution>Novant Health, </institution></institution-wrap>Winston-Salem, NC USA </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01xdqrp08</institution-id><institution-id institution-id-type="GRID">grid.410513.2</institution-id><institution-id institution-id-type="ISNI">0000 0000 8800 7493</institution-id><institution>Pfizer Inc, </institution></institution-wrap>San Francisco, CA USA </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01xdqrp08</institution-id><institution-id institution-id-type="GRID">grid.410513.2</institution-id><institution-id institution-id-type="ISNI">0000 0000 8800 7493</institution-id><institution>Pfizer Inc, </institution></institution-wrap>San Diego, CA USA </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0188v8a70</institution-id><institution-id institution-id-type="GRID">grid.492736.d</institution-id><institution>ICON Plc, </institution></institution-wrap>Blue Bell, Harrisburg, PA USA </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01xdqrp08</institution-id><institution-id institution-id-type="GRID">grid.410513.2</institution-id><institution-id institution-id-type="ISNI">0000 0000 8800 7493</institution-id><institution>Pfizer Inc, </institution></institution-wrap>Groton, CT USA </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04twxam07</institution-id><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution>The University of Texas MD Anderson Cancer Center, </institution></institution-wrap>Houston, TX USA </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>209</volume><issue>3</issue><fpage>613</fpage><lpage>627</lpage><history><date date-type="received"><day>6</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>10</day><month>10</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">To evaluate patient-reported health-related quality-of-life (QoL) in patients with hormone receptor&#x02013;positive/human epidermal growth factor receptor 2&#x02013;negative (HR+/HER2&#x02212;) advanced/metastatic breast cancer (ABC) treated with palbociclib in the longitudinal real-world study, POLARIS.</p></sec><sec><title>Methods</title><p id="Par2">Data were prospectively collected from adult patients with HR+/HER2&#x02212;&#x02009;ABC treated with palbociclib plus endocrine therapy (ET) in routine clinical practice. QoL was assessed with the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire-Core 30 (EORTC QLQ-C30) and reported at baseline and months 6, 12, and 18. Data were expressed as absolute scores at a given time and change from baseline for global QoL and functional/symptom scales. Global Heath Status (GHS)/QoL scores were also determined across 6 patient subgroup categories (e.g., age, visceral disease status). Additionally, the proportions of patients with scores below (functional scales) or above (symptom scales) EORTC-validated thresholds reflecting clinical importance of a health problem were determined.</p></sec><sec><title>Results</title><p id="Par3">Among patients treated with palbociclib plus ET (N&#x02009;=&#x02009;1250) who completed questionnaires at any of the study timepoints, mean GHS/QoL scores at months 6 (69.3), 12 (70.1), and 18 (69.9) were higher than baseline (64.0). Similar trends were observed for functional and symptom scales. Mean GHS/QoL scores over time were consistent across the evaluated subgroups. Decreases in the proportions of patients with clinically important functional impairment/symptoms were observed for most functional/symptom scales from baseline through month 18.</p></sec><sec><title>Conclusion</title><p id="Par4">Findings from this real-world study indicate patients with HR+/HER2&#x02212;&#x02009;ABC treated with palbociclib plus ET maintain their QoL for at least 18&#x000a0;months.</p><p id="Par5">Clinical Trial Registration: NCT03280303; registered 12 September 2017</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s10549-024-07524-2.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>HR+/HER2&#x02212;&#x02009;advanced breast cancer</kwd><kwd>POLARIS</kwd><kwd>Palbociclib</kwd><kwd>Patient-reported outcomes</kwd><kwd>Quality of life</kwd><kwd>Real-world evidence</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par6">Based on clinical trial evidence of improvements in progression-free survival (PFS) without a significant decline in health-related quality of life (QoL), cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in combination with endocrine therapy (ET) are considered the standard of care in patients with hormone receptor&#x02013;positive/human epidermal growth factor receptor 2&#x02013;negative (HR+/HER2&#x02212;) advanced or metastatic breast cancer (ABC) [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>]. Clinical trials provide critical evidence regarding treatment efficacy, safety, and impact on QoL of new therapies in advanced cancers [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>]. However, owing to strict eligibility criteria, clinical trials do not fully reflect the outcomes and experience of patients in routine care, thereby limiting generalizability of trial findings [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par7">To date, there remains a paucity of robust, prospective real-world studies on the QoL of patients receiving newer biological therapies, such as CDK4/6 inhibitors, that have the potential to help guide patient and provider expectations on the impact of treatment [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Thus, POLARIS [<xref ref-type="bibr" rid="CR11">11</xref>], a longitudinal study, was designed to prospectively collect data of patients with HR+/HER2&#x02212;&#x02009;ABC receiving treatment with palbociclib in routine clinical practice. The aim of this study was to evaluate longitudinal patient-reported QoL outcomes in patients who participated in POLARIS and received palbociclib in the real-world setting and to assess for consistency of study findings across patient subgroups often underrepresented in clinical trials.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design</title><p id="Par8">POLARIS (NCT03280303) was a prospective, observational, multicenter, real-world study conducted in&#x02009;&#x0003e;&#x02009;100 sites in the US (majority of sites) and Canada according to each site&#x02019;s routine clinical practice and reviewed and approved by applicable local institutional review boards (enrollment: 1 January 2017&#x02009;&#x02212;&#x02009;30 September 2019); study design is shown in Online Resource 1). Detailed methods have been previously published [<xref ref-type="bibr" rid="CR11">11</xref>].</p></sec><sec id="Sec4"><title>Patient population</title><p id="Par9">POLARIS enrolled adult patients (&#x02265;&#x02009;18&#x000a0;years of age) with a diagnosis of HR+/HER2&#x02212;&#x02009;ABC who received palbociclib (treatment indication determined by a physician) as first-line (1L), second-line (2L), or later line of therapy (LOT). Study inclusion/exclusion criteria are provided in Online Resource 2. Patients were followed from initiation of palbociclib treatment up to 3&#x000a0;years after the end of treatment, patient study withdrawal, or death, whichever came first. Patient characteristics, treatment, and QoL data were collected from routine clinical assessments performed by treating physicians.</p></sec><sec id="Sec5"><title>Patient-reported QoL assessments</title><p id="Par10">One of the outcomes of interest for this analysis was to evaluate patient-reported assessment of global health status (GHS)/QoL using the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 (EORTC QLQ-C30) version 3 questions, #29: &#x0201c;How would you rate your overall health during the past week?&#x0201d; and #30: &#x0201c;How would you rate your overall quality of life during the past week?&#x0201d; [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Additional outcomes evaluated included patient-reported assessment of five functional scales (physical, role, social, emotional, and cognitive) and nine symptom scales (fatigue, pain, nausea/vomiting, insomnia, appetite loss, constipation, dyspnea, diarrhea, and financial difficulties) on the EORTC QLQ-C30. EORTC QLQ-C30 data were collected and analyzed at baseline (i.e., date of study enrollment when informed consent was obtained and inclusion/exclusion criteria assessed) and at months 6, 12, and 18 for those patients still receiving palbociclib treatment.</p><p id="Par11">Proportions of patients with clinically important impairments/symptoms on the functional and symptom scales of the EORTC QLQ-C30, as defined by the EORTC Quality of Life Group [<xref ref-type="bibr" rid="CR14">14</xref>], were also determined.</p></sec><sec id="Sec6"><title>Statistical analyses</title><p id="Par12">Descriptive analyses of EORTC QLQ-C30 data were performed on the overall study population (N&#x02009;=&#x02009;1250 patients) and were repeated for the per-label population (n&#x02009;=&#x02009;861), consisting of patients with HR+/HER2&#x02212;&#x02009;ABC in the study population who were treated as per the US label indication, defined as palbociclib plus aromatase inhibitor in the 1L setting or palbociclib plus fulvestrant after prior ET in any setting [<xref ref-type="bibr" rid="CR15">15</xref>]. Patient characteristics were summarized descriptively and were reported for both study populations. For the overall study population, discontinuation of palbociclib and study withdrawal, with reasons, are reported.</p><p id="Par13">Completion rates of the GHS/QoL domain of the EORTC QLQ-C30 were determined at baseline and months 6, 12, and 18. Patient characteristics were additionally summarized for those patients who completed at least the GHS/QoL domain at months 6, 12, and 18. Multivariable logistic regression analyses were conducted to determine the impact of key patient characteristics (e.g., age at enrollment, race/ethnicity, time from diagnosis to enrollment) on the probability of completing the GHS/QoL domain of the EORTC QLQ-C30 at study time points.</p><p id="Par14">For GHS/QoL and functional and symptom scales, mean scores and standard deviations (SD) were reported at baseline and months 6, 12, and 18. For all 15 components, patient responses were converted to a 0&#x02013;100 scale using the standard EORTC scoring algorithm [<xref ref-type="bibr" rid="CR16">16</xref>]. A higher score for GHS/QoL and functional scales represents a high QoL and high level of functioning, whereas for symptom scales, a higher score represents a high level of symptomatology. Missing (not completed) data on the questionnaires were handled as described in Online Resource 3. For all components of the EORTC QLQ-C30, a sensitivity analysis of mean scores was conducted that only included patients with completed questionnaires at baseline throughout month 18. Additionally, a statistical analysis of the differences in mean scores for GHS/QoL for various combinations of questionnaire completers versus non-completers was conducted using two-group independent sample t-tests. Mean EORTC QLQ-C30 scores were also compared with the US population normative data [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par15">Pre-planned subgroup analyses of GHS/QoL scores by age (&#x0003c;&#x02009;70 versus&#x02009;&#x02265;&#x02009;70&#x000a0;years), race/ethnicity (Black, Indigenous, and People of Color [BIPOC] versus White/Not Hispanic), visceral disease at baseline (yes/no), bone-only metastases at baseline (yes/no), LOT (1L versus&#x02009;&#x02265;&#x02009;2L), and any dose modification(s) (yes/no) were conducted. Significant differences in GHS/QoL mean scores of the subgroups at each time point were determined based on two-group independent sample t-tests [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par16">Changes from baseline in mean scores to months 6, 12, and 18 were determined for the GHS/QoL, functional, and symptom scales; a&#x02009;&#x02265;&#x02009;10-point change in mean score was considered clinically meaningful [<xref ref-type="bibr" rid="CR18">18</xref>]. Statistical comparisons were made based on paired t-tests of mean changes from baseline [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par17">Lastly, EORTC QLQ-C30 data were analyzed as the count and percentage of patients with a health problem (functional impairment/cancer-related symptoms) at baseline, and at months 6, 12, and 18 with functional scale scores below the clinical importance threshold and with symptom scale scores above the clinical importance threshold [<xref ref-type="bibr" rid="CR14">14</xref>].</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Patient baseline characteristics</title><p id="Par18">Between January 2017 and January 2023, 1250 patients were enrolled and received at least one dose of palbociclib. Median time from ABC diagnosis to study enrollment was 1.3&#x000a0;months, median age was 64.0&#x000a0;years, 98.8% were female, 81.8% were White, and 11.1% were Black (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Among the study population, 94.9% had metastatic disease at time of enrollment and 5.0% had locally advanced disease. Among the patients with metastatic disease, 41.7% had visceral disease and 34.1% had bone-only disease. Most of enrolled patients (72.1%) received palbociclib in the 1L setting (median duration of treatment was 14.2&#x000a0;months); 15.0% and 13.0% received palbociclib as 2L and&#x02009;&#x0003e;&#x02009;2L, respectively (median duration of&#x02009;&#x02265;&#x02009;2L treatment was 9.2&#x000a0;months).<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Patient baseline demographic and disease characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristics</th><th align="left">Patients (N&#x02009;=&#x02009;1250)</th></tr></thead><tbody><tr><td align="left" colspan="2">Age at enrollment, years</td></tr><tr><td align="left"><bold>Median (range)</bold></td><td align="left">64.0 (22&#x02013;97)</td></tr><tr><td align="left" colspan="2">Distribution, n (%)</td></tr><tr><td align="left">&#x02009;&#x0003c;&#x02009;50</td><td align="left">193 (15.5)</td></tr><tr><td align="left">50&#x02013;69</td><td align="left">640 (51.4)</td></tr><tr><td align="left">&#x02009;&#x02265;&#x02009;70</td><td align="left">413 (33.1)</td></tr><tr><td align="left" colspan="2">Sex, n (%)</td></tr><tr><td align="left">Male</td><td align="left">15 (1.2)</td></tr><tr><td align="left">Female</td><td align="left">1235 (98.8)</td></tr><tr><td align="left" colspan="2">Race, n (%)</td></tr><tr><td align="left">American Indian or Alaska Native</td><td align="left">8 (0.6)</td></tr><tr><td align="left">Asian</td><td align="left">23 (1.8)</td></tr><tr><td align="left">Black</td><td align="left">139 (11.1)</td></tr><tr><td align="left">Native Hawaiian or other Pacific Islander</td><td align="left">5 (0.4)</td></tr><tr><td align="left">White</td><td align="left">1022 (81.8)</td></tr><tr><td align="left">Other</td><td align="left">22 (1.8)</td></tr><tr><td align="left">Not reported/missing</td><td align="left">31 (2.5)</td></tr><tr><td align="left" colspan="2">Ethnicity, n (%)</td></tr><tr><td align="left">Hispanic or Latino</td><td align="left">106 (8.5)</td></tr><tr><td align="left">Not Hispanic or Latino</td><td align="left">1106 (88.5)</td></tr><tr><td align="left">Not reported/missing</td><td align="left">38 (3.0)</td></tr><tr><td align="left" colspan="2">Disease stage at enrollment, n (%)</td></tr><tr><td align="left">Locally advanced</td><td align="left">62 (5.0)</td></tr><tr><td align="left">Metastatic</td><td align="left">1186 (94.9)</td></tr><tr><td align="left">Not reported</td><td align="left">2 (0.2)</td></tr><tr><td align="left" rowspan="2"><p>Site of distant metastases at ABC diagnosis<sup>a</sup></p><p>Visceral disease</p></td><td align="left"/></tr><tr><td align="left">494 (41.7)</td></tr><tr><td align="left">Bone-only</td><td align="left">405 (34.1)</td></tr><tr><td align="left">Bone plus other metastases</td><td align="left">481 (40.6)</td></tr><tr><td align="left" colspan="2">Disposition at enrollment, n (%)</td></tr><tr><td align="left">Recurrent from earlier stage, stages 0&#x02013;III</td><td align="left">849 (67.9)</td></tr><tr><td align="left">De novo, stage IV at/near initial diagnosis</td><td align="left">341 (27.3)</td></tr><tr><td align="left">Not reported</td><td align="left">60 (4.8)</td></tr><tr><td align="left" colspan="2">Time from ABC diagnosis to enrollment, months</td></tr><tr><td align="left">Median (range)</td><td align="left">1.3 (0&#x02013;248)</td></tr><tr><td align="left">Missing, n</td><td align="left">4</td></tr><tr><td align="left" colspan="2">Distribution, n (%)</td></tr><tr><td align="left">&#x02009;&#x02264;&#x02009;1&#x000a0;month</td><td align="left">514 (41.3)</td></tr><tr><td align="left">&#x02009;&#x0003e;&#x02009;1&#x02013;2&#x000a0;months</td><td align="left">245 (19.7)</td></tr><tr><td align="left">&#x02009;&#x0003e;&#x02009;2&#x02013;6&#x000a0;months</td><td align="left">128 (10.3)</td></tr><tr><td align="left">&#x02009;&#x0003e;&#x02009;6&#x000a0;months</td><td align="left">359 (28.8)</td></tr><tr><td align="left" colspan="2">Line of therapy<sup>b</sup>, n (%)</td></tr><tr><td align="left">1L</td><td align="left">901 (72.1)</td></tr><tr><td align="left">2L</td><td align="left">187 (15.0)</td></tr><tr><td align="left">&#x02009;&#x0003e;&#x02009;2L</td><td align="left">162 (13.0)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Among patients with metastatic disease at study enrollment. Visceral disease refers to metastases of the brain, liver, and/or lung/pleura. <sup>b</sup>Line of therapy (LOT) is defined as the number of systemic therapies taken after initial diagnoses of advanced or metastatic breast cancer, but before palbociclib treatment start. First-line patients had no LOT before palbociclib initiation. <italic>1L</italic> first-line, <italic>2L</italic> second-line,&#x02009;<italic>&#x0003e;&#x02009;2L</italic>, greater than second-line, <italic>ABC</italic>, advanced or metastatic breast cancer</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec9"><title>Discontinuation and withdrawal</title><p id="Par19">Among the study population, 85.4% (n&#x02009;=&#x02009;1068) of patients discontinued palbociclib over the study course. Reasons for treatment discontinuation included disease progression (60.4%), toxicities/side effects (9.7%), patient decision (8.8%), patient physical status (3.0%), completion of planned treatment course (2.3%), poor adherence (0.8%), developed resistance to ET (0.3%), and other (13.7%) or unknown reason (0.9%). After palbociclib discontinuation, patients were followed for a median of 2.9&#x000a0;months; at the end of this follow-up period, 95.6% (n&#x02009;=&#x02009;1195) of patients had discontinued from the study; reasons included death (42.3%), study terminated by sponsor (32.1%), patient no longer willing to participate in study (8.5%), lost to follow-up (3.3%), adverse event (1.7%), and other reason (12.3%).</p></sec><sec id="Sec10"><title>EORTC QLQ-C30 completion rates: GHS/QoL domain</title><p id="Par20">Completion rates for the GHS/QoL domain were 93.4% (n&#x02009;=&#x02009;1167; 83 missing) at baseline, 58.6% (n&#x02009;=&#x02009;732; 518 missing) at month 6, 38.7% (n&#x02009;=&#x02009;484; 766 missing) at month 12, and 28.2% (n&#x02009;=&#x02009;353; 897 missing) at month 18; patient characteristics of each subgroup are shown in Online Resource 4. Generally, the characteristics of patients completing follow-up questionnaires were consistent with those who completed baseline questionnaires (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). From the multivariable regression analyses (Online Resource 5), the most consistent predictive factors of EORTC QLQ-C30 completion included the time from diagnosis date to study enrollment (greater duration versus less) and diagnosis at enrollment (recurrent from earlier stage [stages 0&#x02013;III] versus de novo stage IV).</p></sec><sec id="Sec11"><title>Mean scores on EORTC QLQ-C30 components</title><p id="Par21">Among patients treated with palbociclib plus ET who completed their questionnaires at any of the study time points, mean GHS/QoL scores at months 6 (69.3), 12 (70.1), and 18 (69.9) were higher than recorded at baseline (64.0) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a). The same trend was also observed in the sensitivity analysis conducted with only patients who completed questionnaires at baseline throughout month 18 (n&#x02009;=&#x02009;246); mean GHS/QoL scores at months 6 (72.9), 12 (71.6), and 18 (69.5) were higher than that recorded at baseline (67.9) (Online Resource 6). Mean score for GHS/QoL among patients who only completed the EORTC QLQ-C30 at baseline was 8.1 points (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) lower than for patients who completed additional time points beyond baseline (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Although some significant differences in GHS/QoL scores were found between those who completed and those who did not complete the questionnaire at different time points, these differences were less than the 10-point clinically meaningful threshold (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Mean scores of <bold>a</bold> GHS/QoL, <bold>b</bold> functional domains, and <bold>c</bold> symptom domains as measured by the EORTC QLQ-C30. <sup>a</sup>Mean scores were assessed among the patients with completed EORTC QLQ-C30 questionnaires at the indicated timepoints. Error bars represent standard deviation. Note: a higher score for GHS/QoL and functional scales indicates improvement, whereas for symptom scales, a higher score indicates greater severity of symptoms. EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30; GHS/QoL, global health status/quality of life</p></caption><graphic xlink:href="10549_2024_7524_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Differences in mean scores for GHS/QoL among varying levels of questionnaire completion</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">GHS/QoL completion</th><th align="left">Difference in means<sup>a</sup><break/>(95% CI)<sup>b</sup></th><th align="left"><italic>P</italic>-value<sup>a</sup></th></tr></thead><tbody><tr><td align="left">Only at baseline (n&#x02009;=&#x02009;393) vs at baseline and month 6 (n&#x02009;=&#x02009;246)</td><td align="left">&#x02009;&#x02212;&#x02009;4.5 (&#x02212;&#x02009;8.4,&#x02009;&#x02212;&#x02009;0.6)</td><td char="." align="char">0.023</td></tr><tr><td align="left">Only at baseline (n&#x02009;=&#x02009;393) vs at baseline, month 6, and month 12 (n&#x02009;=&#x02009;162)</td><td align="left">&#x02009;&#x02212;&#x02009;6.3 (&#x02212;&#x02009;10.7,&#x02009;&#x02212;&#x02009;1.9)</td><td char="." align="char">0.006</td></tr><tr><td align="left">Only at baseline (n&#x02009;=&#x02009;393) vs at baseline, month 6, 12, and 18 (n&#x02009;=&#x02009;246)</td><td align="left">&#x02009;&#x02212;&#x02009;8.1 (&#x02212;&#x02009;12.0,&#x02009;&#x02212;&#x02009;4.3)</td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">At baseline and month 6 (n&#x02009;=&#x02009;246) vs at baseline, month 6, and month 12 (n&#x02009;=&#x02009;162)</td><td align="left">&#x02009;&#x02212;&#x02009;1.8 (&#x02212;&#x02009;6.4, 2.8)</td><td char="." align="char">0.442</td></tr><tr><td align="left">At baseline and month 6 (n&#x02009;=&#x02009;246) vs at baseline, month 6, 12, and 18 (n&#x02009;=&#x02009;246)</td><td align="left">&#x02009;&#x02212;&#x02009;3.7 (&#x02212;&#x02009;7.7, 0.4)</td><td char="." align="char">0.077</td></tr><tr><td align="left">At baseline, month 6, and 12 (n&#x02009;=&#x02009;162) vs at baseline, month 6, 12, and 18 (n&#x02009;=&#x02009;246)</td><td align="left">&#x02009;&#x02212;&#x02009;1.9 (&#x02212;&#x02009;6.3. 2.6)</td><td char="." align="char">0.411</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>The difference in means is mean score of fewer measurements (e.g., only at baseline minus mean score of more completed measurements [e.g., at baseline and month 6]). <sup>b</sup>According to two-group independent sample t-test. CI, confidence interval; GHS/QoL, global health status/quality of life</p></table-wrap-foot></table-wrap></p><p id="Par22">Among patients treated with palbociclib plus ET who completed their questionnaires at any of the study time points, mean scores of the functional scales also remained stable from baseline to month 18, ranging from 70.5 &#x02013; 79.2 at baseline, 76.1&#x02009;&#x02212;&#x02009;80.7 at month 6, 77.0&#x02009;&#x02212;&#x02009;81.1 at month 12, and 77.0&#x02009;&#x02212;&#x02009;82.2 at month 18 (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b). Likewise, mean scores of the symptom scales remained generally stable with some numerical improvement observed from baseline to month 18 (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>c). Similar trends were observed in the sensitivity analysis of only patients who completed questionnaires at baseline throughout month 18 (Online Resource 7).</p></sec><sec id="Sec12"><title>Comparison with normative data</title><p id="Par23">GHS/QoL scores seen at baseline (64.0) through study month 18 (69.9) were similar or numerically higher than in the general US population (63.9) (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>) [<xref ref-type="bibr" rid="CR17">17</xref>]. These similarities held true for the majority of the functional scales. Regarding mean scores on the symptom scales, in which lower scores indicate less symptom severity, at month 18, pain, nausea/vomiting, insomnia, constipation, and diarrhea were numerically lower than corresponding (US population) normative data.<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Mean EORTC QLQ-C30 scores compared with US normative data</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">POLARIS Mean score (SD)</th><th align="left">US normative data (n&#x02009;=&#x02009;1009)<sup>e</sup> Mean score (SD)</th></tr></thead><tbody><tr><td align="left" colspan="3">GHS/QoL</td></tr><tr><td align="left"><p><bold>Baseline</bold><sup>a</sup></p><p>Month 6<sup>b</sup></p><p>Month 12<sup>c</sup></p></td><td align="left"><p>64.0 (23.7)</p><p>69.3 (21.2)</p><p>70.1 (20.2)</p></td><td align="left">63.9 (22.9)</td></tr><tr><td align="left">Month 18<sup>d</sup></td><td align="left">69.9 (21.3)</td><td align="left"/></tr><tr><td align="left" colspan="3">Functional scales</td></tr><tr><td align="left" rowspan="2"><p>Physical</p><p>Baseline</p><p>Month 6</p><p>Month 12</p></td><td align="left"/><td align="left" rowspan="2">80.8 (25.2)</td></tr><tr><td align="left"><p>73.4 (24.7)</p><p>77.0 (22.1)</p><p>77.0 (21.6)</p></td></tr><tr><td align="left">Month 18</td><td align="left">77.0 (22.5)</td><td align="left"/></tr><tr><td align="left"><p>Role</p><p>Baseline</p><p>Month 6</p><p>Month 12</p></td><td align="left"><p>70.5 (32.7)</p><p>76.1 (27.8)</p><p>77.3 (26.7)</p></td><td align="left">81.7 (28.2)</td></tr><tr><td align="left">Month 18</td><td align="left">77.6 (27.1)</td><td align="left"/></tr><tr><td align="left"><p>Social</p><p>Baseline</p><p>Month 6</p><p>Month 12</p><p>Month 18</p></td><td align="left"><p>74.8 (29.5)</p><p>80.7 (25.0)</p><p>81.1 (25.2)</p><p>82.2 (22.9)</p></td><td align="left">81.6 (29.4)</td></tr><tr><td align="left"><p>Emotional</p><p>Baseline</p><p>Month 6</p><p>Month 12</p><p>Month 18</p></td><td align="left"><p>74.4 (23.1)</p><p>79.7 (20.3)</p><p>80.5 (21.0)</p><p>81.6 (18.4)</p></td><td align="left">73.3 (28.0)</td></tr><tr><td align="left"><p>Cognitive</p><p>Baseline</p><p>Month 6</p><p>Month 12</p><p>Month 18</p></td><td align="left"><p>79.2 (24.0)</p><p>80.4 (21.4)</p><p>80.6 (22.9)</p><p>78.8 (22.3)</p></td><td align="left">80.9 (25.6)</td></tr><tr><td align="left" colspan="3">Symptom scales</td></tr><tr><td align="left"><p>Fatigue</p><p>Baseline</p><p>Month 6</p><p>Month 12</p><p>Month 18</p></td><td align="left"><p>36.5 (26.8)</p><p>34.2 (23.1)</p><p>32.9 (24.5)</p><p>31.8 (24.2)</p></td><td align="left">31.9 (27.8)</td></tr><tr><td align="left"><p>Pain</p><p>Baseline</p><p>Month 6</p><p>Month 12</p><p>Month 18</p></td><td align="left"><p>34.7 (31.6)</p><p>26.6 (26.3)</p><p>26.4 (27.3)</p><p>25.0 (27.3)</p></td><td align="left">27.5 (30.2)</td></tr><tr><td align="left"><p>Nausea/vomiting</p><p>Baseline</p><p>Month 6</p><p>Month 12</p><p>Month 18</p></td><td align="left"><p>12.1 (20.8)</p><p>9.4 (17.3)</p><p>9.8 (17.2)</p><p>8.9 (16.6)</p></td><td align="left">10.9 (22.6)</td></tr><tr><td align="left"><p>Insomnia</p><p>Baseline</p><p>Month 6</p><p>Month 12</p><p>Month 18</p></td><td align="left"><p>31.5 (31.0)</p><p>29.2 (28.8)</p><p>26.6 (28.8)</p><p>25.7 (27.6)</p></td><td align="left">30.8 (33.2)</td></tr><tr><td align="left"><p>Appetite loss</p><p>Baseline</p><p>Month 6</p><p>Month 12</p><p>Month 18</p></td><td align="left"><p>23.2 (30.0)</p><p>17.0 (25.0)</p><p>15.9 (25.4)</p><p>16.6 (25.5)</p></td><td align="left">14.1 (25.3)</td></tr><tr><td align="left"><p>Constipation</p><p>Baseline</p><p>6&#x000a0;months</p><p>12&#x000a0;months</p><p>18&#x000a0;months</p></td><td align="left"><p>18.8 (27.4)</p><p>15.6 (23.6)</p><p>15.1 (23.7)</p><p>15.9 (23.6)</p></td><td align="left">18.6 (28.6)</td></tr><tr><td align="left"><p>Dyspnea</p><p>Baseline</p><p>6&#x000a0;months</p><p>12&#x000a0;months</p><p>18&#x000a0;months</p></td><td align="left"><p>23.0 (28.8)</p><p>19.1 (24.6)</p><p>18.4 (24.4)</p><p>20.2 (23.6)</p></td><td align="left">19.9 (28.5)</td></tr><tr><td align="left"><p>Diarrhea</p><p>Baseline</p><p>6&#x000a0;months</p><p>12&#x000a0;months</p><p>18&#x000a0;months</p></td><td align="left"><p>12.7 (23.2)</p><p>12.9 (22.6)</p><p>10.7 (20.3)</p><p>12.3 (22.0)</p></td><td align="left">13.7 (27.1)</td></tr><tr><td align="left"><p>Financial difficulties</p><p>Baseline</p><p>6&#x000a0;months</p><p>12&#x000a0;months</p><p>18&#x000a0;months</p></td><td align="left"><p>26.6 (33.3)</p><p>22.6 (30.3)</p><p>20.0 (27.8)</p><p>19.0 (26.9)</p></td><td align="left">17.5 (30.8)</td></tr></tbody></table><table-wrap-foot><p>A higher score for GHS/QoL and functional scales indicates improvement, whereas for symptom scales, a higher score indicates greater severity of symptoms. <sup>a</sup>n&#x02009;=&#x02009;1167; <sup>b</sup>n&#x02009;=&#x02009;732; <sup>c</sup>n&#x02009;=&#x02009;484; <sup>d</sup>n&#x02009;=&#x02009;353; <sup>e</sup>Source of US population norm&#x02013;Nolte et al., 2019 [<xref ref-type="bibr" rid="CR17">17</xref>]</p><p>EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30; GHS/QoL, global health status/quality of life; SD, standard deviation</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec13"><title>Subgroup analyses</title><p id="Par24">Across the six subgroup categories analyzed (age at baseline [&#x0003c;&#x02009;70 versus&#x02009;&#x02265;&#x02009;70&#x000a0;years], race [BIPOC versus White], visceral disease at baseline [yes/no], bone-only metastases at baseline [yes/no], LOT [1L versus&#x02009;&#x02265;&#x02009;2L], and any dose modification [yes/no]), mean GHS/QoL scores did not significantly differ at months 6, 12, and 18 (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Subgroup analyses of mean scores of GHS/QoL. Error bars represent standard deviation. Significant differences in GHS/QoL mean scores of the subgroups at each time point were determined based on two-group independent sample t-tests, with the corresponding reflecting the difference between subgroups at that particular time point. Mean scores were assessed among patients with completed EORTC QLQ-C30 questionnaires at the indicated timepoints. Age&#x02013;baseline:&#x02009;&#x0003c;&#x02009;70&#x000a0;years, n&#x02009;=&#x02009;767;&#x02009;&#x02265;&#x02009;70&#x000a0;years, n&#x02009;=&#x02009;399; Month 6:&#x02009;&#x0003c;&#x02009;70&#x000a0;years, n&#x02009;=&#x02009;485;&#x02009;&#x02265;&#x02009;70&#x000a0;years, n&#x02009;=&#x02009;247; Month 12:&#x02009;&#x0003c;&#x02009;70&#x000a0;years, n&#x02009;=&#x02009;321;&#x02009;&#x02265;&#x02009;70&#x000a0;years, n&#x02009;=&#x02009;163; Month 18:&#x02009;&#x0003c;&#x02009;70&#x000a0;years, n&#x02009;=&#x02009;230;&#x02009;&#x02265;&#x02009;70&#x000a0;years, n&#x02009;=&#x02009;123. Race &#x02013; baseline: BIPOC, n&#x02009;=&#x02009;257; White, n&#x02009;=&#x02009;867; Month 6: BIPOC, n&#x02009;=&#x02009;147; White, n&#x02009;=&#x02009;558; Month 12: BIPOC, n&#x02009;=&#x02009;94; White, n&#x02009;=&#x02009;370; Month 18: BIPOC, n&#x02009;=&#x02009;70; White, n&#x02009;=&#x02009;270. Visceral disease &#x02013; baseline: yes, n&#x02009;=&#x02009;460; no, n&#x02009;=&#x02009;707; Month 6: yes, n&#x02009;=&#x02009;268; no, n&#x02009;=&#x02009;464; Month 12: yes, n&#x02009;=&#x02009;179; no, n&#x02009;=&#x02009;305; Month 18: yes, n&#x02009;=&#x02009;123; no, n&#x02009;=&#x02009;230. Bone-only metastases &#x02013; baseline: yes, n&#x02009;=&#x02009;383; no, n&#x02009;=&#x02009;784; Month 6: yes, n&#x02009;=&#x02009;249; no, n&#x02009;=&#x02009;483; Month 12: yes, n&#x02009;=&#x02009;169; no, n&#x02009;=&#x02009;315; Month 18: yes, n&#x02009;=&#x02009;125; no, n&#x02009;=&#x02009;228. LOT&#x02013;baseline: 1L, n&#x02009;=&#x02009;842;&#x02009;&#x02265;&#x02009;2L, n&#x02009;=&#x02009;325; Month 6: 1L, n&#x02009;=&#x02009;548;&#x02009;&#x02265;&#x02009;2L, n&#x02009;=&#x02009;184; Month 12: 1L, n&#x02009;=&#x02009;365;&#x02009;&#x02265;&#x02009;2L, n&#x02009;=&#x02009;119; Month 18: 1L, n&#x02009;=&#x02009;274;&#x02009;&#x02265;&#x02009;2L, n&#x02009;=&#x02009;79. Any dose modification &#x02013; baseline: yes, n&#x02009;=&#x02009;449; no, n&#x02009;=&#x02009;718; Month 6: yes, n&#x02009;=&#x02009;330; no, n&#x02009;=&#x02009;402; Month 12: yes, n&#x02009;=&#x02009;244; no, n&#x02009;=&#x02009;240; Month 18: yes, n&#x02009;=&#x02009;192; no, n&#x02009;=&#x02009;161. 1L, first-line;&#x02009;&#x02265;&#x02009;2L, second-line or later; BIPOC, Black, Indigenous, and People of Color; GHS/QoL, global health status/quality of life; LOT, line of therapy</p></caption><graphic xlink:href="10549_2024_7524_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec14"><title>Mean changes from baseline on EORTC QLQ-C30 components</title><p id="Par25">Mean changes from baseline in GHS/QoL scores at months 6 (3.5 [95% CI: 1.9, 5.2], <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) and 12 (2.5 [95% CI: 0.4, 4.6], <italic>P</italic>&#x02009;=&#x02009;0.022) reached statistical significance, suggesting improvement, but did not reach the 10-point clinically meaningful threshold (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a). Mean changes from baseline ranged from &#x02212;&#x000a0;0.9 to 6.0 across the functional scales and from&#x02009;&#x02212;&#x02009;7.6 to 0.8 across the symptom scales (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>b and c). The largest improvement from baseline was seen in the pain scale, reaching&#x02009;&#x02212;&#x02009;7.6 at month 18 (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), with most of this change already evident by month 6 (&#x02212;&#x02009;6.9; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001). None of the mean changes in the scales achieved the 10-point clinically meaningful threshold.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Mean change from baseline in mean scores of <bold>a</bold> GHS/QoL, <bold>b</bold> functional domains, and <bold>c</bold> symptom domains as measured by the EORTC-QLQ-C30 A higher score for GHS/QoL and functional scales indicates improvement, whereas for symptom scales, a higher score indicates greater severity of symptoms (i.e., deterioration). Mean change from baseline represents mean score postbaseline minus mean score at baseline. <italic>P</italic>-values determined from paired t-test of mean changes from baseline. CI, confidence interval; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30; GHS/QoL, global health status/quality of life</p></caption><graphic xlink:href="10549_2024_7524_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec15"><title>Proportions of patients with clinically important functional/symptom impairment</title><p id="Par26">The proportions of patients with scores below clinical importance thresholds [<xref ref-type="bibr" rid="CR14">14</xref>] from baseline up to month 18 numerically trended lower for all functional domains, except cognitive, which was numerically higher by 3.5% (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). For all symptom domains the proportions also trended lower over time, except for dyspnea and diarrhea, which trended slightly upward by 2.5% and 0.5%, respectively (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>). The greatest decline was seen in the proportion of patients with clinically important pain, which decreased from 52.9% at baseline to 41.1% at month 18. These trends were relatively consistent when only patients with data reported at every time point were included in the analysis (n&#x02009;=&#x02009;246; Online Resources 7 and 8).<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Patients with functional scale scores below the clinical importance threshold, suggesting a health problem</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Functional scale</th><th align="left" rowspan="2">Clinical importance threshold [<xref ref-type="bibr" rid="CR14">14</xref>]</th><th align="left" colspan="4">Patients with scores below threshold, n (%)</th></tr><tr><th align="left">Baseline<sup>a,b</sup></th><th align="left">Month 6<sup>a,b</sup></th><th align="left">Month 12<sup>a,b</sup></th><th align="left">Month 18<sup>a,b</sup></th></tr></thead><tbody><tr><td align="left">Physical<sup>c</sup></td><td align="left">&#x02009;&#x0003c;&#x02009;83</td><td align="left">636 (54.4)</td><td align="left">368 (50.2)</td><td align="left">242 (49.9)</td><td align="left">168 (47.3)</td></tr><tr><td align="left">Role<sup>c</sup></td><td align="left">&#x02009;&#x0003c;&#x02009;58</td><td align="left">333 (28.5)</td><td align="left">147 (20.1)</td><td align="left">92 (19.0)</td><td align="left">64 (18.0)</td></tr><tr><td align="left">Social<sup>d</sup></td><td align="left">&#x02009;&#x0003c;&#x02009;58</td><td align="left">278 (23.8)</td><td align="left">110 (15.0)</td><td align="left">73 (15.1)</td><td align="left">47 (13.3)</td></tr><tr><td align="left">Emotional<sup>e</sup></td><td align="left">&#x02009;&#x0003c;&#x02009;71</td><td align="left">430 (36.8)</td><td align="left">215 (29.3)</td><td align="left">143 (29.6)</td><td align="left">97 (27.4)</td></tr><tr><td align="left">Cognitive<sup>e</sup></td><td align="left">&#x02009;&#x0003c;&#x02009;75</td><td align="left">395 (33.8)</td><td align="left">254 (34.7)</td><td align="left">155 (32.0)</td><td align="left">132 (37.3)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>The number of patients eligible at a visit is based on data expected to be available through the latest date of exposure, visit date, or questionnaire date (baseline, n&#x02009;=&#x02009;1250; month 6, n&#x02009;=&#x02009;1100; month 12, n&#x02009;=&#x02009;978; month 18, n&#x02009;=&#x02009;834). <sup>b</sup>Percentages for functional scales were calculated based on &#x0201c;n,&#x0201d; the number of patients with functional score measurements available. <sup>c</sup>n (missing): baseline, 1170 (80); month 6, 733 (367); month 12, 485 (493); month 18, 355 (479). <sup>d</sup>n (missing): baseline, 1169 (81); month 6, 732 (368); month 12, 484 (494); month 18, 354 (480). <sup>e</sup>n (missing): baseline, 1169 (81); month 6, 733 (367); month 12, 484 (494); month 18, 354 (480)</p></table-wrap-foot></table-wrap><table-wrap id="Tab5"><label>Table&#x000a0;5</label><caption><p>Patients with symptom scale scores above the clinical importance threshold, suggesting a health problem</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Symptom scale</th><th align="left" rowspan="2">Clinical importance threshold [<xref ref-type="bibr" rid="CR14">14</xref>]</th><th align="left" colspan="4">Patients with scores above threshold, n (%)</th></tr><tr><th align="left">Baseline<sup>a,b</sup></th><th align="left">Month 6<sup>a,b</sup></th><th align="left">Month 12<sup>a,b</sup></th><th align="left">Month 18<sup>a,b</sup></th></tr></thead><tbody><tr><td align="left">Fatigue<sup>c</sup></td><td align="left">&#x02009;&#x0003e;&#x02009;39</td><td align="left">427 (36.5)</td><td align="left">258 (35.2)</td><td align="left">146 (30.1)</td><td align="left">106 (29.4)</td></tr><tr><td align="left">Pain<sup>d</sup></td><td align="left">&#x02009;&#x0003e;&#x02009;25</td><td align="left">619 (52.9)</td><td align="left">345 (47.1)</td><td align="left">224 (46.2)</td><td align="left">146 (41.1)</td></tr><tr><td align="left">Nausea/vomiting<sup>d</sup></td><td align="left">&#x02009;&#x0003e;&#x02009;8</td><td align="left">424 (36.2)</td><td align="left">236 (32.2)</td><td align="left">159 (32.8)</td><td align="left">114 (32.1)</td></tr><tr><td align="left">Insomnia<sup>e</sup></td><td align="left">&#x02009;&#x0003e;&#x02009;50</td><td align="left">280 (24.0)</td><td align="left">156 (21.3)</td><td align="left">90 (18.6)</td><td align="left">62 (17.5)</td></tr><tr><td align="left">Appetite loss<sup>e</sup></td><td align="left">&#x02009;&#x0003e;&#x02009;50</td><td align="left">208 (17.8)</td><td align="left">72 (9.8)</td><td align="left">50 (10.3)</td><td align="left">39 (11.0)</td></tr><tr><td align="left">Constipation<sup>c</sup></td><td align="left">&#x02009;&#x0003e;&#x02009;50</td><td align="left">141 (12.1)</td><td align="left">70 (9.6)</td><td align="left">46 (9.5)</td><td align="left">28 (7.9)</td></tr><tr><td align="left">Dyspnea<sup>f</sup></td><td align="left">&#x02009;&#x0003e;&#x02009;17</td><td align="left">556 (47.6)</td><td align="left">327 (44.7)</td><td align="left">211 (43.5)</td><td align="left">178 (50.1)</td></tr><tr><td align="left">Diarrhea<sup>g</sup></td><td align="left">&#x02009;&#x0003e;&#x02009;17</td><td align="left">330 (28.3)</td><td align="left">212 (28.9)</td><td align="left">124 (25.6)</td><td align="left">101 (28.8)</td></tr><tr><td align="left">Financial difficulties<sup>h</sup></td><td align="left">&#x02009;&#x0003e;&#x02009;17</td><td align="left">564 (48.4)</td><td align="left">326 (44.5)</td><td align="left">201 (41.7)</td><td align="left">144 (40.8)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>The number of patients eligible at a visit is based on data expected to be available through the latest date of exposure, visit date, or questionnaire date (baseline, n&#x02009;=&#x02009;1250; month 6, n&#x02009;=&#x02009;1100; month 12, n&#x02009;=&#x02009;978; month 18, n&#x02009;=&#x02009;834). <sup>b</sup>Percentages for symptom scales were calculated based on &#x0201c;n,&#x0201d; the number of patients with symptom score measurements available. <sup>c</sup>n (missing): baseline, 1170 (80); month 6, 733 (367); month 12, 485 (493); month 18, 354 (480). <sup>d</sup>n (missing): baseline, 1170 (80); month 6, 733 (367); month 12, 485 (493); month 18, 355 (479). <sup>e</sup>n (missing): baseline, 1169 (81); month 6, 733 (367); month 12, 485 (493); month 18, 354 (480). <sup>f</sup>n (missing): baseline, 1167 (83); month 6, 731 (369); month 12, 485 (493); month 18, 355 (479). <sup>g</sup>n (missing): baseline, 1167 (83); month 6, 733 (367); month 12, 484 (494); month 18, 351 (483). <sup>h</sup>n (missing): baseline, 1166 (84); month 6, 733 (367); month 12, 482 (496); month 18, 353 (481)</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec16"><title>Patient-reported QoL assessments in the per-label population</title><p id="Par27">The per-label population included 861 patients, representing 68.9% of the overall study population. Among this population, 82.7% received palbociclib in the 1L setting; 8.6% and 8.7% received palbociclib as 2L and&#x02009;&#x0003e;&#x02009;2L, respectively. Characteristics for this population were generally consistent with the overall study population; notable differences included that a greater proportion were treated with 1L palbociclib (~&#x02009;10% more) (Online Resource 9). Online Resource 10 shows the characteristics of patients who completed the EORTC QLQ-C30 at months 6, 12, and 18.</p><p id="Par28">The findings of patient-reported QoL assessments in the per-label population were consistent with that of the overall study population. The difference in mean scores for GHS/QoL among patients who completed the EORTC QLQ-C30 only at baseline versus those who completed it at all time points was &#x02212;&#x000a0;7.4 (<italic>P</italic>&#x02009;=&#x02009;0.002; Online Resource 11). Among the patients treated with palbociclib plus ET who completed additional questionnaires at any of the study time points, mean GHS/QoL scores at months 6 (69.7), 12 (71.0), and 18 (69.9) were higher than that recorded at baseline (63.8) (Online Resources 12 and 13). Mean scores of the functional and symptom scales also remained stable from baseline to month 18 (Online Resource 13). Across the six subgroup categories analyzed, mean GHS/QoL scores did not significantly differ at months 6, 12, and 18 (Online Resource 14).</p><p id="Par29">Similar to in the overall study population, mean changes from baseline in GHS/QoL scores at month 6 (5.0 [95% CI: 3.1, 6.9], <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) and 12 (3.5 [95% CI: 1.1, 5.9], <italic>P</italic>&#x02009;=&#x02009;0.004) reached statistical significance, suggesting improvement, but did not reach the 10-point clinically meaningful threshold (Online Resource 15). Mean changes from baseline in functional and symptom scales also did not exceed the 10-point clinically meaningful threshold (Online Resource 15). Numerically, decreases in the proportions of patients with scores below clinical importance thresholds (suggestive of a health problem) from baseline up to month 18 were observed for all functional domains, except cognitive (Online Resource 16), and for all symptom domains, except dyspnea (Online Resource 17); the proportion of patients with scores below the threshold trended numerically higher in the cognitive domain and in the symptom domain, dyspnea.</p></sec></sec><sec id="Sec17"><title>Discussion</title><p id="Par30">The findings of this real-world study indicate that patients with HR+/HER2&#x02212;&#x02009;ABC treated with palbociclib plus ET in routine clinical practice maintain QoL for at least 18&#x000a0;months of treatment, with GHS/QoL scores averaging 64.0 at baseline and 69.3, 70.1, and 69.9 at months 6, 12, and 18, respectively, while patients continued receiving treatment. Findings among patients treated in routine clinical practice align relatively closely with the results of the PALOMA-3 trial, in which QoL was also measured with the EORTC QLQ-C30 GHS/QoL score [<xref ref-type="bibr" rid="CR5">5</xref>]. In PALOMA-3, GHS/QoL scores averaged 65.9 at baseline and 66.1 post-treatment among those who received palbociclib plus fulvestrant [<xref ref-type="bibr" rid="CR5">5</xref>]. Furthermore, our 18-month GHS/QoL data corroborates and extends the reported 36% reduction in risk of QoL deterioration found in PALOMA-3 among patients treated with palbociclib plus fulvestrant relative to those treated with placebo plus fulvestrant after approximately 12&#x000a0;months [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par31">The QoL scores observed in POLARIS among patients with HR+/HER2&#x02212;&#x02009;ABC were also relatively similar to that of US population normative data [<xref ref-type="bibr" rid="CR17">17</xref>]. A similar observation was made in PALOMA-2 based on Functional Assessment of Cancer Therapy-Breast (FACT-B) normative standards [<xref ref-type="bibr" rid="CR4">4</xref>]. The real-world patient-reported assessments of QoL while on active treatment with palbociclib in this prospective study provide further evidence of the favorable risk&#x02013;benefit profile of palbociclib plus ET in the treatment of HR+/HER2&#x02212;&#x02009;ABC. A recently published systematic review of 15 studies (7 randomized controlled trials, 3 single-arm clinical trials, and 5 real-world studies, including POLARIS study findings reported in published conference abstracts) that evaluated QoL outcomes in patients with HR+/HER2&#x02212;&#x02009;ABC treated with palbociclib has also concluded that across different study types, populations, palbociclib LOTs, and various QoL measurement instruments, QoL is at least maintained if not improved from baseline in patients treated with palbociclib [<xref ref-type="bibr" rid="CR19">19</xref>]. These findings with palbociclib are in agreement with the multitude of studies that have evaluated QoL in patients treated with CDK4/6 inhibitors in general, with a systematic review of 31 clinical trials and 7 real-world studies concluding QoL is not adversely impacted by the addition of CDK4/6 inhibitors to ET in patients with estrogen receptor-positive/HER2&#x02212;&#x02009;ABC [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par32">In both of these systematic reviews, it was expressed that it was a challenge to compare QoL results across studies because the main heterogeneity of the studies was the variety of QoL measurement instruments used; however, the EORTC QLQ-C30 was the most prominently used QoL measurement instrument [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Currently, there is an international initiative (Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data Consortium) aimed at standardizing design, analysis, presentation, and interpretation of patient-reported outcomes data in cancer research&#x000a0;[<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. A recent interview of patients in Europe and the US with different types of cancer, including breast cancer, has found that among participants, the concepts included in the EORTC QLQ-C30 are broadly understood across language versions, and that items included in the instrument are valid and relevant to patients with different cancer sites, stages, and treatments for the assessment of functional health, symptom burden, and QoL [<xref ref-type="bibr" rid="CR22">22</xref>]. In our study we limited the number of questionnaires to reduce patient burden. Nonetheless, while the generic EORTC QLQ-30 is suitable to assess quality of life in patients with breast cancer, as well as other cancers, we encourage that future research supplement the EORTC QLQ-30 with a disease-specific measure such as the EORTC QLQ-BR45 [<xref ref-type="bibr" rid="CR23">23</xref>], an improved extension of the QLQ-BR23 that was not available when our study began, or another suitable alternative.</p><p id="Par33">The findings of POLARIS on QoL are encouraging compared with other limited real-world evidence of the QoL in patients with ABC treated mostly with non-targeted therapies. A retrospective QoL analysis of patients with ABC (n&#x02009;=&#x02009;306) from the German PRAEGNANT registry reported an EORTC QLQ-C30 global QoL score of 56.8 in patients without progression (mean reference for patients with ABC: 60.2 [<xref ref-type="bibr" rid="CR24">24</xref>]), versus 52.2 in those with progression (n&#x02009;=&#x02009;65) [<xref ref-type="bibr" rid="CR25">25</xref>]. At baseline, approximately one-third of patients in this PRAEGNANT cohort had received chemotherapy, known to be associated with lower QoL scores relative to ET [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR26">26</xref>], and no patients had recorded CDK4/6 inhibitor use [<xref ref-type="bibr" rid="CR25">25</xref>]. In another real-world QoL study conducted in 5 European countries (70%&#x02009;&#x02212;&#x02009;94% treated with ET only), the EORTC QLQ-C30 derived global QoL in women with HR+/HER2&#x02212;&#x02009;ABC (n&#x02009;=&#x02009;781) averaged 50.9 [<xref ref-type="bibr" rid="CR27">27</xref>], significantly lower than the mean reference value of 60.2 for patients with ABC [<xref ref-type="bibr" rid="CR24">24</xref>], and European general population mean of 72.3 for women aged 60&#x02009;&#x02212;&#x02009;69&#x000a0;years [<xref ref-type="bibr" rid="CR28">28</xref>]. Interestingly, POLARIS GHS/QoL average scores are also higher than the EORTC QLQ-C30 ABC reference values provided by the EORTC group itself, with published means ranging from 54.6 to 57.6 [<xref ref-type="bibr" rid="CR29">29</xref>].</p><p id="Par34">In this study, mean changes in EORTC QLQ-C30 functioning and symptom scale scores showed improvement over the course of the study in terms of both mean values (although like GHS/QoL, none crossed the 10-point clinically meaningful threshold) and percentage of patients crossing clinical importance thresholds. The most improvement was seen in the pain scale with an average decrease of 7.6 points by month 18 and 11.8% decline in the proportion of patients above the clinical importance threshold of&#x02009;&#x0003e;&#x02009;25, which is consistent with findings of the PALOMA-2 and PALOMA-3 QoL analyses [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. The observed decline in pain may have contributed to the improvements in functioning and overall QoL; further research is warranted. The decline in pain severity that we observed in POLARIS could in part be attributed to 75% of enrolled patients having bone metastases at diagnosis (34.1% bone-only, 40.6% bone plus other metastases). We did find small numerically trending higher proportions of patients over time with health problems in the cognitive domain (3.5%), and symptoms of dyspnea (2.5%) and diarrhea (0.5%). However, mean changes indicating deterioration in these scales were less than 1 point and not considered clinically meaningful.</p><p id="Par35">As with many real-world studies, the interpretation of the findings of this study is subject to limitations. For example, per the observational study design, patient selection and treatment and monitoring procedures were determined by the treating physician in routine clinical practice rather than dictated by a protocol [<xref ref-type="bibr" rid="CR11">11</xref>], which may have contributed to the fact that approximately one-third of the study population was not treated per-label. The heterogeneous, less-selective patient populations in this study increase the difficulty of interpreting outcomes data [<xref ref-type="bibr" rid="CR11">11</xref>], and causality cannot be confirmed between treatments and outcomes. Also, it is beyond the scope of these analyses to examine the effects of discontinuation, disease progression, or other factors. Furthermore, the lack of blinding to treatment and missing or inaccurate data on the assessments at follow-up visits must be acknowledged.</p><p id="Par36">Consistent with other prospective real-world studies in the advanced cancers setting [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>], there was significant sample attrition in EORTC QLQ-C30 completion over time, which may have led to selection bias due to attrition of the most unwell participants [<xref ref-type="bibr" rid="CR31">31</xref>]. Of note, 393 of 1250 patients completed the GHS/QoL only at baseline. However, patient characteristics were similar between baseline and all study timepoints analyzed, suggesting that there was no tangible or obvious evidence of subpopulation selection bias. Missing questionnaires (i.e., attrition) is common in real-world studies, usually through negative events experienced by patients (e.g., disease progression, treatment toxicities, death, loss to follow-up, COVID-19), which clearly occurred in POLARIS (i.e., 95.6% of patients withdrew from the study [planned analysis of up to 3&#x000a0;years post-treatment], 42.3% because of death).</p><p id="Par37">Also notable is a survey that reported around a third of POLARIS study sites experienced some impact on their responsiveness to correspondence, timely data entry, or patient management due to the COVID-19 pandemic [<xref ref-type="bibr" rid="CR32">32</xref>]. We did find in the sensitivity analyses of patients who provided continual completed questionnaire submissions, EORTC QLQ-C30 (GHS/QoL domain) mean values over time were relatively consistent with the main analysis, further suggesting that attrition may have not introduced sizable or dominant bias. Lastly, POLARIS, regarding QoL outcomes, was designed to characterize the QoL of patients who were actively receiving palbociclib treatment, and as patients discontinued palbociclib over the course of the POLARIS study, they no longer completed QoL assessments.</p></sec><sec id="Sec18"><title>Conclusion</title><p id="Par38">In this real-world prospective study, among patients with HR+/HER2&#x02212;&#x02009;ABC and recorded measurements on the EORTC QLQ-C30, QoL was generally maintained while on treatment with palbociclib plus ET. While there was some numerical improvement observed in functioning and symptoms including, most notably, less pain severity, the magnitude of improvement did not reach clinically meaningful thresholds. Overall QoL was also preserved in all evaluated patient subgroups and was found to be fairly equivalent to that in the general US population. These findings are consistent with the patient-reported outcomes and well-tolerated safety profile reported in the PALOMA clinical trials investigating palbociclib plus ET [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>].</p></sec><sec id="Sec19" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="10549_2024_7524_MOESM1_ESM.docx"><caption><p>Supplementary file1 (DOCX 774 KB)</p></caption></media></supplementary-material></p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This study was sponsored by Pfizer Inc. Medical writing support was provided by Sophie Wicken, Melissa Lingohr-Smith, and Martin Dalziel of Oxford PharmaGenesis Inc., Newtown, PA, USA, and was funded by Pfizer Inc.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Conception/design: GR, EG, DT and JCC. Provision of study material or patients: GR, JLB, TP and DT. Collection and/or assembly of data: MZM, JCC. Data analysis and interpretation: GR, EG, JLB, DT, MZM and JCC. Manuscript writing and revision: GR, JLB, YJ, TP, JM, SL, EJ, EG, YW, MZM, JCC, MSK and DT. Final approval of submitted manuscript: All authors.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was sponsored by Pfizer Inc.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See <ext-link ext-link-type="uri" xlink:href="https://www.pfizer.com/science/clinical-trials/trial-data-and-results">https://www.pfizer.com/science/clinical-trials/trial-data-and-results</ext-link> for more information.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par39">Gabrielle Rocque: receives research funding from Genentech, Pfizer, Daiichi Sankyo; paid consultant: Pfizer, Gilead, and Armada. Joanne L. Blum: paid consultant: Pfizer, Inc., Tempus, TD2; Speaker's Bureau: Pfizer, Tempus. Yan Ji: received compensation for advisory board: AstraZeneca, BMS. Timothy Pluard: paid consultant: Pfizer, AstraZeneca, Jazz Pharmaceutical, Daiichi, Gilead; research funding (institution): Daiichi Sankyo, Jazz Pharmaceuticals, Pfizer, Sermonix, Scorpion, Merck, DualityBio, Arvinas; Speaker&#x02019;s Bureau: Gilead, AstraZeneca, Stemline. John Migas: contracted research (clinical trials) paid to institution (Pfizer, Inc., AstraZeneca, Jazz Pharmaceuticals. Shailendra Lakhanpal: reports no conflicts of interest. Erin Jepsen: employed by Novant Health Cancer Institute. Eric Gauthier: Pfizer employee and owns PFE stock. Yao Wang: Pfizer employee and owns PFE stock. Monica Z. Montelongo: employee of ICON, which was a paid consultant to Pfizer in connection with the development of this manuscript. Joseph C. Cappelleri: Pfizer employee and owns PFE stock Meghan S. Karuturi: reports no conflicts of interest. Debu Tripathy: contracted research (clinical trials) paid to institution: Novartis, Pfizer, Polyphor; paid consultant: AstraZeneca, OncoPep, GlaxoSmithKline, Gilead, Personalis, Sermonix, Pfizer, AMBRX, Novartis, Puma Biotechnology, Roche, Menarini, BeiGene, Jazz Pharmaceuticals.</p></notes><notes id="FPar2"><title>Ethical approval</title><p id="Par40">The study protocol, protocol amendments, final approved informed consent and assent documents, and all relevant supporting information were submitted by the investigator to the institutional review board (IRB) and approved by the IRB and regulatory agency (as appropriate) before study initiation.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>JJ</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Bloomquist</surname><given-names>E</given-names></name><name><surname>Sanchez</surname><given-names>J</given-names></name><name><surname>Wedam</surname><given-names>SB</given-names></name><name><surname>Singh</surname><given-names>H</given-names></name><name><surname>Amiri-Kordestani</surname><given-names>L</given-names></name><name><surname>Ibrahim</surname><given-names>A</given-names></name><name><surname>Sridhara</surname><given-names>R</given-names></name><name><surname>Goldberg</surname><given-names>KB</given-names></name><name><surname>Theoret</surname><given-names>MR</given-names></name><name><surname>Kluetz</surname><given-names>PG</given-names></name><name><surname>Blumenthal</surname><given-names>GM</given-names></name><name><surname>Pazdur</surname><given-names>R</given-names></name><name><surname>Beaver</surname><given-names>JA</given-names></name><name><surname>Prowell</surname><given-names>TM</given-names></name></person-group><article-title>CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US food and drug administration pooled analysis</article-title><source>Lancet Oncol</source><year>2020</year><volume>21</volume><fpage>250</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(19)30804-6</pub-id><pub-id pub-id-type="pmid">31859246</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Gao JJ, Cheng J, Bloomquist E, Sanchez J, Wedam SB, Singh H, Amiri-Kordestani L, Ibrahim A, Sridhara R, Goldberg KB, Theoret MR, Kluetz PG, Blumenthal GM, Pazdur R, Beaver JA, Prowell TM (2020) CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US food and drug administration pooled analysis. Lancet Oncol 21:250&#x02013;260. 10.1016/S1470-2045(19)30804-6<pub-id pub-id-type="pmid">31859246</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Burstein</surname><given-names>HJ</given-names></name><name><surname>Somerfield</surname><given-names>MR</given-names></name><name><surname>Barton</surname><given-names>DL</given-names></name><name><surname>Dorris</surname><given-names>A</given-names></name><name><surname>Fallowfield</surname><given-names>LJ</given-names></name><name><surname>Jain</surname><given-names>D</given-names></name><name><surname>Johnston</surname><given-names>SRD</given-names></name><name><surname>Korde</surname><given-names>LA</given-names></name><name><surname>Litton</surname><given-names>JK</given-names></name><name><surname>Macrae</surname><given-names>ER</given-names></name><name><surname>Peterson</surname><given-names>LL</given-names></name><name><surname>Vikas</surname><given-names>P</given-names></name><name><surname>Yung</surname><given-names>RL</given-names></name><name><surname>Rugo</surname><given-names>HS</given-names></name></person-group><article-title>Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update</article-title><source>J Clin Oncol</source><year>2021</year><volume>39</volume><fpage>3959</fpage><lpage>3977</lpage><pub-id pub-id-type="doi">10.1200/jco.21.01392</pub-id><pub-id pub-id-type="pmid">34324367</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Burstein HJ, Somerfield MR, Barton DL, Dorris A, Fallowfield LJ, Jain D, Johnston SRD, Korde LA, Litton JK, Macrae ER, Peterson LL, Vikas P, Yung RL, Rugo HS (2021) Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update. J Clin Oncol 39:3959&#x02013;3977. 10.1200/jco.21.01392<pub-id pub-id-type="pmid">34324367</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Gennari</surname><given-names>A</given-names></name><name><surname>Andr&#x000e9;</surname><given-names>F</given-names></name><name><surname>Barrios</surname><given-names>CH</given-names></name><name><surname>Cort&#x000e9;s</surname><given-names>J</given-names></name><name><surname>de Azambuja</surname><given-names>E</given-names></name><name><surname>DeMichele</surname><given-names>A</given-names></name><name><surname>Dent</surname><given-names>R</given-names></name><name><surname>Fenlon</surname><given-names>D</given-names></name><name><surname>Gligorov</surname><given-names>J</given-names></name><name><surname>Hurvitz</surname><given-names>SA</given-names></name><name><surname>Im</surname><given-names>SA</given-names></name><name><surname>Krug</surname><given-names>D</given-names></name><name><surname>Kunz</surname><given-names>WG</given-names></name><name><surname>Loi</surname><given-names>S</given-names></name><name><surname>Penault-Llorca</surname><given-names>F</given-names></name><name><surname>Ricke</surname><given-names>J</given-names></name><name><surname>Robson</surname><given-names>M</given-names></name><name><surname>Rugo</surname><given-names>HS</given-names></name><name><surname>Saura</surname><given-names>C</given-names></name><name><surname>Schmid</surname><given-names>P</given-names></name><name><surname>Singer</surname><given-names>CF</given-names></name><name><surname>Spanic</surname><given-names>T</given-names></name><name><surname>Tolaney</surname><given-names>SM</given-names></name><name><surname>Turner</surname><given-names>NC</given-names></name><name><surname>Curigliano</surname><given-names>G</given-names></name><name><surname>Loibl</surname><given-names>S</given-names></name><name><surname>Paluch-Shimon</surname><given-names>S</given-names></name><name><surname>Harbeck</surname><given-names>N</given-names></name></person-group><article-title>ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer</article-title><source>Ann Oncol</source><year>2021</year><volume>32</volume><fpage>1475</fpage><lpage>1495</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2021.09.019</pub-id><pub-id pub-id-type="pmid">34678411</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Gennari A, Andr&#x000e9; F, Barrios CH, Cort&#x000e9;s J, de Azambuja E, DeMichele A, Dent R, Fenlon D, Gligorov J, Hurvitz SA, Im SA, Krug D, Kunz WG, Loi S, Penault-Llorca F, Ricke J, Robson M, Rugo HS, Saura C, Schmid P, Singer CF, Spanic T, Tolaney SM, Turner NC, Curigliano G, Loibl S, Paluch-Shimon S, Harbeck N (2021) ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 32:1475&#x02013;1495. 10.1016/j.annonc.2021.09.019<pub-id pub-id-type="pmid">34678411</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Rugo</surname><given-names>HS</given-names></name><name><surname>Dieras</surname><given-names>V</given-names></name><name><surname>Gelmon</surname><given-names>KA</given-names></name><name><surname>Finn</surname><given-names>RS</given-names></name><name><surname>Slamon</surname><given-names>DJ</given-names></name><name><surname>Martin</surname><given-names>M</given-names></name><name><surname>Neven</surname><given-names>P</given-names></name><name><surname>Shparyk</surname><given-names>Y</given-names></name><name><surname>Mori</surname><given-names>A</given-names></name><name><surname>Lu</surname><given-names>DR</given-names></name><name><surname>Bhattacharyya</surname><given-names>H</given-names></name><name><surname>Bartlett</surname><given-names>C</given-names></name><name><surname>Iyer</surname><given-names>S</given-names></name><name><surname>Johnston</surname><given-names>S</given-names></name><name><surname>Ettl</surname><given-names>J</given-names></name><name><surname>Harbeck</surname><given-names>N</given-names></name></person-group><article-title>Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial</article-title><source>Ann Oncol</source><year>2018</year><volume>29</volume><fpage>888</fpage><lpage>894</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdy012</pub-id><pub-id pub-id-type="pmid">29360932</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Rugo HS, Dieras V, Gelmon KA, Finn RS, Slamon DJ, Martin M, Neven P, Shparyk Y, Mori A, Lu DR, Bhattacharyya H, Bartlett C, Iyer S, Johnston S, Ettl J, Harbeck N (2018) Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Ann Oncol 29:888&#x02013;894. 10.1093/annonc/mdy012<pub-id pub-id-type="pmid">29360932</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Harbeck</surname><given-names>N</given-names></name><name><surname>Iyer</surname><given-names>S</given-names></name><name><surname>Turner</surname><given-names>N</given-names></name><name><surname>Cristofanilli</surname><given-names>M</given-names></name><name><surname>Ro</surname><given-names>J</given-names></name><name><surname>Andr&#x000e9;</surname><given-names>F</given-names></name><name><surname>Loi</surname><given-names>S</given-names></name><name><surname>Verma</surname><given-names>S</given-names></name><name><surname>Iwata</surname><given-names>H</given-names></name><name><surname>Bhattacharyya</surname><given-names>H</given-names></name><name><surname>Puyana Theall</surname><given-names>K</given-names></name><name><surname>Bartlett</surname><given-names>CH</given-names></name><name><surname>Loibl</surname><given-names>S</given-names></name></person-group><article-title>Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial</article-title><source>Ann Oncol</source><year>2016</year><volume>27</volume><fpage>1047</fpage><lpage>1054</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdw139</pub-id><pub-id pub-id-type="pmid">27029704</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Harbeck N, Iyer S, Turner N, Cristofanilli M, Ro J, Andr&#x000e9; F, Loi S, Verma S, Iwata H, Bhattacharyya H, Puyana Theall K, Bartlett CH, Loibl S (2016) Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Ann Oncol 27:1047&#x02013;1054. 10.1093/annonc/mdw139<pub-id pub-id-type="pmid">27029704</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Di Lauro</surname><given-names>V</given-names></name><name><surname>Barchiesi</surname><given-names>G</given-names></name><name><surname>Martorana</surname><given-names>F</given-names></name><name><surname>Zucchini</surname><given-names>G</given-names></name><name><surname>Muratore</surname><given-names>M</given-names></name><name><surname>Fontanella</surname><given-names>C</given-names></name><name><surname>Arpino</surname><given-names>G</given-names></name><name><surname>Del Mastro</surname><given-names>L</given-names></name><name><surname>Giuliano</surname><given-names>M</given-names></name><name><surname>Puglisi</surname><given-names>F</given-names></name><name><surname>De Laurentiis</surname><given-names>M</given-names></name></person-group><article-title>Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review</article-title><source>ESMO Open</source><year>2022</year><volume>7</volume><fpage>100629</fpage><pub-id pub-id-type="doi">10.1016/j.esmoop.2022.100629</pub-id><pub-id pub-id-type="pmid">36399953</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Di Lauro V, Barchiesi G, Martorana F, Zucchini G, Muratore M, Fontanella C, Arpino G, Del Mastro L, Giuliano M, Puglisi F, De Laurentiis M (2022) Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review. ESMO Open 7:100629. 10.1016/j.esmoop.2022.100629<pub-id pub-id-type="pmid">36399953</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Batra</surname><given-names>A</given-names></name><name><surname>Kong</surname><given-names>S</given-names></name><name><surname>Cheung</surname><given-names>WY</given-names></name></person-group><article-title>Eligibility of real-world patients with metastatic breast cancer for clinical trials</article-title><source>Breast</source><year>2020</year><volume>54</volume><fpage>171</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1016/j.breast.2020.10.005</pub-id><pub-id pub-id-type="pmid">33120082</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Batra A, Kong S, Cheung WY (2020) Eligibility of real-world patients with metastatic breast cancer for clinical trials. Breast 54:171&#x02013;178. 10.1016/j.breast.2020.10.005<pub-id pub-id-type="pmid">33120082</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Dodwell</surname><given-names>D</given-names></name><name><surname>Shakir</surname><given-names>R</given-names></name></person-group><article-title>Assessing new drugs in advanced cancer: beyond randomised evidence</article-title><source>Clin Oncol (R Coll Radiol)</source><year>2021</year><volume>33</volume><fpage>e201</fpage><lpage>e202</lpage><pub-id pub-id-type="doi">10.1016/j.clon.2020.11.003</pub-id><pub-id pub-id-type="pmid">33223383</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Dodwell D, Shakir R (2021) Assessing new drugs in advanced cancer: beyond randomised evidence. Clin Oncol (R Coll Radiol) 33:e201&#x02013;e202. 10.1016/j.clon.2020.11.003<pub-id pub-id-type="pmid">33223383</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>M</given-names></name><name><surname>Pearson</surname><given-names>SA</given-names></name><name><surname>Simes</surname><given-names>RJ</given-names></name><name><surname>Chua</surname><given-names>BH</given-names></name></person-group><article-title>Harnessing real-world evidence to advance cancer research</article-title><source>Curr Oncol</source><year>2023</year><volume>30</volume><fpage>1844</fpage><lpage>1859</lpage><pub-id pub-id-type="doi">10.3390/curroncol30020143</pub-id><pub-id pub-id-type="pmid">36826104</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Tang M, Pearson SA, Simes RJ, Chua BH (2023) Harnessing real-world evidence to advance cancer research. Curr Oncol 30:1844&#x02013;1859. 10.3390/curroncol30020143<pub-id pub-id-type="pmid">36826104</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Harbeck</surname><given-names>N</given-names></name><name><surname>Bartlett</surname><given-names>M</given-names></name><name><surname>Spurden</surname><given-names>D</given-names></name><name><surname>Hooper</surname><given-names>B</given-names></name><name><surname>Zhan</surname><given-names>L</given-names></name><name><surname>Rosta</surname><given-names>E</given-names></name><name><surname>Cameron</surname><given-names>C</given-names></name><name><surname>Mitra</surname><given-names>D</given-names></name><name><surname>Zhou</surname><given-names>A</given-names></name></person-group><article-title>CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies</article-title><source>Future Oncol</source><year>2021</year><volume>17</volume><fpage>2107</fpage><lpage>2122</lpage><pub-id pub-id-type="doi">10.2217/fon-2020-1264</pub-id><pub-id pub-id-type="pmid">33663223</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Harbeck N, Bartlett M, Spurden D, Hooper B, Zhan L, Rosta E, Cameron C, Mitra D, Zhou A (2021) CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies. Future Oncol 17:2107&#x02013;2122. 10.2217/fon-2020-1264<pub-id pub-id-type="pmid">33663223</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Tripathy</surname><given-names>D</given-names></name><name><surname>Blum</surname><given-names>JL</given-names></name><name><surname>Rocque</surname><given-names>GB</given-names></name><name><surname>Bardia</surname><given-names>A</given-names></name><name><surname>Karuturi</surname><given-names>MS</given-names></name><name><surname>Cappelleri</surname><given-names>JC</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Davis</surname><given-names>KL</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone receptor-positive advanced breast cancer</article-title><source>Future Oncol</source><year>2020</year><volume>16</volume><fpage>2475</fpage><lpage>2485</lpage><pub-id pub-id-type="doi">10.2217/fon-2020-0573</pub-id><pub-id pub-id-type="pmid">32787449</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Tripathy D, Blum JL, Rocque GB, Bardia A, Karuturi MS, Cappelleri JC, Liu Y, Zhang Z, Davis KL, Wang Y (2020) POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone receptor-positive advanced breast cancer. Future Oncol 16:2475&#x02013;2485. 10.2217/fon-2020-0573<pub-id pub-id-type="pmid">32787449</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Aaronson</surname><given-names>NK</given-names></name><name><surname>Ahmedzai</surname><given-names>S</given-names></name><name><surname>Bergman</surname><given-names>B</given-names></name><name><surname>Bullinger</surname><given-names>M</given-names></name><name><surname>Cull</surname><given-names>A</given-names></name><name><surname>Duez</surname><given-names>NJ</given-names></name><name><surname>Filiberti</surname><given-names>A</given-names></name><name><surname>Flechtner</surname><given-names>H</given-names></name><name><surname>Fleishman</surname><given-names>SB</given-names></name><name><surname>de Haes</surname><given-names>JC</given-names></name><etal/></person-group><article-title>The european organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology</article-title><source>J Natl Cancer Inst</source><year>1993</year><volume>85</volume><fpage>365</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1093/jnci/85.5.365</pub-id><pub-id pub-id-type="pmid">8433390</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The european organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365&#x02013;376. 10.1093/jnci/85.5.365<pub-id pub-id-type="pmid">8433390</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">EORTC Quality of Life Group (1995) EORTC QLQ-C30 (version 3). <ext-link ext-link-type="uri" xlink:href="https://www.eortc.org/app/uploads/sites/2/2018/08/Specimen-QLQ-C30-English.pdf">https://www.eortc.org/app/uploads/sites/2/2018/08/Specimen-QLQ-C30-English.pdf</ext-link>. Accessed 5 June 2024</mixed-citation></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Giesinger</surname><given-names>JM</given-names></name><name><surname>Loth</surname><given-names>FL</given-names></name><name><surname>Aaronson</surname><given-names>NK</given-names></name><name><surname>Arraras</surname><given-names>JI</given-names></name><name><surname>Caocci</surname><given-names>G</given-names></name><name><surname>Efficace</surname><given-names>F</given-names></name><name><surname>Groenvold</surname><given-names>M</given-names></name><name><surname>van Leeuwen</surname><given-names>M</given-names></name><name><surname>Petersen</surname><given-names>MA</given-names></name><name><surname>Ramage</surname><given-names>J</given-names></name><name><surname>Tomaszewski</surname><given-names>KA</given-names></name></person-group><article-title>Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research</article-title><source>J Clin Epidemiol</source><year>2020</year><volume>118</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.jclinepi.2019.10.003</pub-id><pub-id pub-id-type="pmid">31639445</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Giesinger JM, Loth FL, Aaronson NK, Arraras JI, Caocci G, Efficace F, Groenvold M, van Leeuwen M, Petersen MA, Ramage J, Tomaszewski KA (2020) Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. J Clin Epidemiol 118:1&#x02013;8. 10.1016/j.jclinepi.2019.10.003<pub-id pub-id-type="pmid">31639445</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Pfizer Labs (2023) IBRANCE (palbociclib) - Highlights of prescribing information. <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207103s008lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207103s008lbl.pdf</ext-link>. Accessed 29 March 2024.</mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Fayers P, Machin D (2016) Quality of life: the assessment, analysis and reporting of patient-reported outcomes. 3rd edn. Wiley-Blackwell. Chichester, UK</mixed-citation></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Nolte</surname><given-names>S</given-names></name><name><surname>Liegl</surname><given-names>G</given-names></name><name><surname>Petersen</surname><given-names>MA</given-names></name><name><surname>Aaronson</surname><given-names>NK</given-names></name><name><surname>Costantini</surname><given-names>A</given-names></name><name><surname>Fayers</surname><given-names>PM</given-names></name><name><surname>Gr&#x000f8;nvold</surname><given-names>M</given-names></name><name><surname>Holzner</surname><given-names>B</given-names></name><name><surname>Johnson</surname><given-names>CD</given-names></name><name><surname>Kemmler</surname><given-names>G</given-names></name><name><surname>Tomaszewski</surname><given-names>KA</given-names></name></person-group><article-title>General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States</article-title><source>European J Cancer</source><year>2019</year><volume>107</volume><fpage>153</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2018.11.024</pub-id><pub-id pub-id-type="pmid">30576971</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Nolte S, Liegl G, Petersen MA, Aaronson NK, Costantini A, Fayers PM, Gr&#x000f8;nvold M, Holzner B, Johnson CD, Kemmler G, Tomaszewski KA (2019) General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States. European J Cancer 107:153&#x02013;163. 10.1016/j.ejca.2018.11.024<pub-id pub-id-type="pmid">30576971</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Osoba</surname><given-names>D</given-names></name><name><surname>Rodrigues</surname><given-names>G</given-names></name><name><surname>Myles</surname><given-names>J</given-names></name><name><surname>Zee</surname><given-names>B</given-names></name><name><surname>Pater</surname><given-names>J</given-names></name></person-group><article-title>Interpreting the significance of changes in health-related quality-of-life scores</article-title><source>J Clin Oncol</source><year>1998</year><volume>16</volume><fpage>139</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1200/jco.1998.16.1.139</pub-id><pub-id pub-id-type="pmid">9440735</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139&#x02013;144. 10.1200/jco.1998.16.1.139<pub-id pub-id-type="pmid">9440735</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Samjoo</surname><given-names>IA</given-names></name><name><surname>Hall</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Nguyen</surname><given-names>BN</given-names></name><name><surname>Bartlett</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>ML</given-names></name><name><surname>Harbeck</surname><given-names>N</given-names></name><name><surname>Cappelleri</surname><given-names>JC</given-names></name><name><surname>Karuturi</surname><given-names>M</given-names></name><name><surname>Makari</surname><given-names>D</given-names></name><name><surname>Arruda</surname><given-names>LS</given-names></name><name><surname>Sandin</surname><given-names>R</given-names></name><name><surname>Hanson</surname><given-names>K</given-names></name><name><surname>Doan</surname><given-names>J</given-names></name></person-group><article-title>A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib</article-title><source>J Comp Eff Res</source><year>2024</year><pub-id pub-id-type="doi">10.57264/cer-2024-0111</pub-id><pub-id pub-id-type="pmid">39254990</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Samjoo IA, Hall A, Chen C, Nguyen BN, Bartlett M, Smith ML, Harbeck N, Cappelleri JC, Karuturi M, Makari D, Arruda LS, Sandin R, Hanson K, Doan J (2024) A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib. J Comp Eff Res. 10.57264/cer-2024-0111<pub-id pub-id-type="pmid">39254990</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Coens</surname><given-names>C</given-names></name><name><surname>Pe</surname><given-names>M</given-names></name><name><surname>Dueck</surname><given-names>AC</given-names></name><name><surname>Sloan</surname><given-names>J</given-names></name><name><surname>Basch</surname><given-names>E</given-names></name><name><surname>Calvert</surname><given-names>M</given-names></name><name><surname>Campbell</surname><given-names>A</given-names></name><name><surname>Cleeland</surname><given-names>C</given-names></name><name><surname>Cocks</surname><given-names>K</given-names></name><name><surname>Collette</surname><given-names>L</given-names></name><name><surname>Devlin</surname><given-names>N</given-names></name></person-group><article-title>International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium</article-title><source>Lancet Oncol</source><year>2020</year><volume>21</volume><issue>2</issue><fpage>e83</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/s1470-2045(19)30790-9</pub-id><pub-id pub-id-type="pmid">32007209</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Coens C, Pe M, Dueck AC, Sloan J, Basch E, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Devlin N (2020) International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium. Lancet Oncol 21(2):e83-96. 10.1016/s1470-2045(19)30790-9<pub-id pub-id-type="pmid">32007209</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Pe</surname><given-names>M</given-names></name><name><surname>Alanya</surname><given-names>A</given-names></name><name><surname>Falk</surname><given-names>RS</given-names></name><name><surname>Amdal</surname><given-names>CD</given-names></name><name><surname>Bjordal</surname><given-names>K</given-names></name><name><surname>Chang</surname><given-names>J</given-names></name><name><surname>Cislo</surname><given-names>P</given-names></name><name><surname>Coens</surname><given-names>C</given-names></name><name><surname>Dirven</surname><given-names>L</given-names></name><name><surname>Speck</surname><given-names>RM</given-names></name><name><surname>Fitzgerald</surname><given-names>K</given-names></name></person-group><article-title>Setting international standards in analyzing patient-reported outcomes and quality of life endpoints in cancer clinical trials-innovative medicines initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures</article-title><source>Lancet Oncol</source><year>2023</year><volume>24</volume><fpage>e270</fpage><lpage>e283</lpage><pub-id pub-id-type="doi">10.1016/s1470-2045(23)00157-2</pub-id><pub-id pub-id-type="pmid">37269858</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Pe M, Alanya A, Falk RS, Amdal CD, Bjordal K, Chang J, Cislo P, Coens C, Dirven L, Speck RM, Fitzgerald K (2023) Setting international standards in analyzing patient-reported outcomes and quality of life endpoints in cancer clinical trials-innovative medicines initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures. Lancet Oncol 24:e270&#x02013;e283. 10.1016/s1470-2045(23)00157-2<pub-id pub-id-type="pmid">37269858</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Cocks</surname><given-names>K</given-names></name><name><surname>Wells</surname><given-names>JR</given-names></name><name><surname>Johnson</surname><given-names>C</given-names></name><name><surname>Schmidt</surname><given-names>H</given-names></name><name><surname>Koller</surname><given-names>M</given-names></name><name><surname>Oerlemans</surname><given-names>S</given-names></name><name><surname>Velikova</surname><given-names>G</given-names></name><name><surname>Pinto</surname><given-names>M</given-names></name><name><surname>Tomaszewski</surname><given-names>KA</given-names></name><name><surname>Aaronson</surname><given-names>NK</given-names></name><name><surname>Exall</surname><given-names>E</given-names></name><name><surname>Finbow</surname><given-names>C</given-names></name><name><surname>Fitzsimmons</surname><given-names>D</given-names></name><name><surname>Grant</surname><given-names>L</given-names></name><name><surname>Groenvold</surname><given-names>M</given-names></name><name><surname>Tolley</surname><given-names>C</given-names></name><name><surname>Wheelwright</surname><given-names>S</given-names></name><name><surname>Bottomley</surname><given-names>A</given-names></name></person-group><article-title>Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer</article-title><source>Eur J Cancer</source><year>2023</year><volume>178</volume><fpage>128</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2022.10.026</pub-id><pub-id pub-id-type="pmid">36436330</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Cocks K, Wells JR, Johnson C, Schmidt H, Koller M, Oerlemans S, Velikova G, Pinto M, Tomaszewski KA, Aaronson NK, Exall E, Finbow C, Fitzsimmons D, Grant L, Groenvold M, Tolley C, Wheelwright S, Bottomley A (2023) Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer. Eur J Cancer 178:128&#x02013;138. 10.1016/j.ejca.2022.10.026<pub-id pub-id-type="pmid">36436330</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Bjelic-Radisic</surname><given-names>V</given-names></name><name><surname>Cardoso</surname><given-names>F</given-names></name><name><surname>Cameron</surname><given-names>D</given-names></name><name><surname>Brain</surname><given-names>E</given-names></name><name><surname>Kuljanic</surname><given-names>K</given-names></name><name><surname>da Costa</surname><given-names>RA</given-names></name><name><surname>Conroy</surname><given-names>T</given-names></name><name><surname>Inwald</surname><given-names>EC</given-names></name><name><surname>Serpentini</surname><given-names>S</given-names></name><name><surname>Pinto</surname><given-names>M</given-names></name><name><surname>Weis</surname><given-names>J</given-names></name><name><surname>Morag</surname><given-names>O</given-names></name><name><surname>Lindviksmoen Astrup</surname><given-names>G</given-names></name><name><surname>Tomaszweksi</surname><given-names>KA</given-names></name><name><surname>Pogoda</surname><given-names>K</given-names></name><name><surname>Sinai</surname><given-names>P</given-names></name><name><surname>Sprangers</surname><given-names>M</given-names></name><name><surname>Aaronson</surname><given-names>N</given-names></name><name><surname>Velikova</surname><given-names>G</given-names></name><name><surname>Greimel</surname><given-names>E</given-names></name><name><surname>Arraras</surname><given-names>J</given-names></name><name><surname>Bottomley</surname><given-names>A</given-names></name></person-group><article-title>An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45</article-title><source>Ann Oncol</source><year>2020</year><volume>31</volume><fpage>283</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2019.10.027</pub-id><pub-id pub-id-type="pmid">31959345</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Bjelic-Radisic V, Cardoso F, Cameron D, Brain E, Kuljanic K, da Costa RA, Conroy T, Inwald EC, Serpentini S, Pinto M, Weis J, Morag O, Lindviksmoen Astrup G, Tomaszweksi KA, Pogoda K, Sinai P, Sprangers M, Aaronson N, Velikova G, Greimel E, Arraras J, Bottomley A (2020) An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45. Ann Oncol 31:283&#x02013;288. 10.1016/j.annonc.2019.10.027<pub-id pub-id-type="pmid">31959345</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Scott NW, Fayers PM, Aaronson NK, Bottomley A, de Graeff A, Groenvold M, Gundy C, Koller M, Petersen MA, Sprangers M, EORTC Quality of Life Group (2008) EORTC QLQ-C30 reference values. Quality of Life Department, EORTC Headquarters. <ext-link ext-link-type="uri" xlink:href="https://www.eortc.org/app/uploads/sites/2/2018/02/reference_values_manual2008.pdf">https://www.eortc.org/app/uploads/sites/2/2018/02/reference_values_manual2008.pdf</ext-link>. Accessed 6 June 2024.</mixed-citation></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>V</given-names></name><name><surname>Nabieva</surname><given-names>N</given-names></name><name><surname>Haberle</surname><given-names>L</given-names></name><name><surname>Taran</surname><given-names>FA</given-names></name><name><surname>Hartkopf</surname><given-names>AD</given-names></name><name><surname>Volz</surname><given-names>B</given-names></name><name><surname>Overkamp</surname><given-names>F</given-names></name><name><surname>Brandl</surname><given-names>AL</given-names></name><name><surname>Kolberg</surname><given-names>HC</given-names></name><name><surname>Hadji</surname><given-names>P</given-names></name><name><surname>Tesch</surname><given-names>H</given-names></name><name><surname>Ettl</surname><given-names>J</given-names></name><name><surname>Lux</surname><given-names>MP</given-names></name><name><surname>Luftner</surname><given-names>D</given-names></name><name><surname>Belleville</surname><given-names>E</given-names></name><name><surname>Fasching</surname><given-names>PA</given-names></name><name><surname>Janni</surname><given-names>W</given-names></name><name><surname>Beckmann</surname><given-names>MW</given-names></name><name><surname>Wimberger</surname><given-names>P</given-names></name><name><surname>Hielscher</surname><given-names>C</given-names></name><name><surname>Fehm</surname><given-names>TN</given-names></name><name><surname>Brucker</surname><given-names>SY</given-names></name><name><surname>Wallwiener</surname><given-names>D</given-names></name><name><surname>Schneeweiss</surname><given-names>A</given-names></name><name><surname>Wallwiener</surname><given-names>M</given-names></name></person-group><article-title>Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry</article-title><source>Breast</source><year>2018</year><volume>37</volume><fpage>154</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1016/j.breast.2017.08.008</pub-id><pub-id pub-id-type="pmid">29237546</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Muller V, Nabieva N, Haberle L, Taran FA, Hartkopf AD, Volz B, Overkamp F, Brandl AL, Kolberg HC, Hadji P, Tesch H, Ettl J, Lux MP, Luftner D, Belleville E, Fasching PA, Janni W, Beckmann MW, Wimberger P, Hielscher C, Fehm TN, Brucker SY, Wallwiener D, Schneeweiss A, Wallwiener M (2018) Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. Breast 37:154&#x02013;160. 10.1016/j.breast.2017.08.008<pub-id pub-id-type="pmid">29237546</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>R</given-names></name><name><surname>Mitra</surname><given-names>D</given-names></name><name><surname>Courcy</surname><given-names>JD</given-names></name><name><surname>Iyer</surname><given-names>S</given-names></name></person-group><article-title>Breast cancer specific quality of life in HR+/HER2- advanced/metastatic breast cancer patients in a real-world setting</article-title><source>J Clin Oncol</source><year>2016</year><volume>34</volume><fpage>554</fpage><pub-id pub-id-type="doi">10.1200/JCO.2016.34.15_suppl.554</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Wood R, Mitra D, Courcy JD, Iyer S (2016) Breast cancer specific quality of life in HR+/HER2- advanced/metastatic breast cancer patients in a real-world setting. J Clin Oncol 34:554. 10.1200/JCO.2016.34.15_suppl.554</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Davie</surname><given-names>A</given-names></name><name><surname>Carter</surname><given-names>GC</given-names></name><name><surname>Rider</surname><given-names>A</given-names></name><name><surname>Pike</surname><given-names>J</given-names></name><name><surname>Lewis</surname><given-names>K</given-names></name><name><surname>Bailey</surname><given-names>A</given-names></name><name><surname>Price</surname><given-names>GL</given-names></name><name><surname>Ringeisen</surname><given-names>F</given-names></name><name><surname>Pivot</surname><given-names>X</given-names></name></person-group><article-title>Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2- advanced breast cancer in five European countries</article-title><source>BMC Cancer</source><year>2020</year><volume>20</volume><fpage>855</fpage><pub-id pub-id-type="doi">10.1186/s12885-020-07294-2</pub-id><pub-id pub-id-type="pmid">32894087</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Davie A, Carter GC, Rider A, Pike J, Lewis K, Bailey A, Price GL, Ringeisen F, Pivot X (2020) Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2- advanced breast cancer in five European countries. BMC Cancer 20:855. 10.1186/s12885-020-07294-2<pub-id pub-id-type="pmid">32894087</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Hinz</surname><given-names>A</given-names></name><name><surname>Singer</surname><given-names>S</given-names></name><name><surname>Brahler</surname><given-names>E</given-names></name></person-group><article-title>European reference values for the quality of life questionnaire EORTC QLQ-C30: results of a German investigation and a summarizing analysis of six European general population normative studies</article-title><source>Acta Oncol</source><year>2014</year><volume>53</volume><fpage>958</fpage><lpage>965</lpage><pub-id pub-id-type="doi">10.3109/0284186X.2013.879998</pub-id><pub-id pub-id-type="pmid">24456505</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Hinz A, Singer S, Brahler E (2014) European reference values for the quality of life questionnaire EORTC QLQ-C30: results of a German investigation and a summarizing analysis of six European general population normative studies. Acta Oncol 53:958&#x02013;965. 10.3109/0284186X.2013.879998<pub-id pub-id-type="pmid">24456505</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Mierzynska</surname><given-names>J</given-names></name><name><surname>Taye</surname><given-names>M</given-names></name><name><surname>Pe</surname><given-names>M</given-names></name><name><surname>Coens</surname><given-names>C</given-names></name><name><surname>Martinelli</surname><given-names>F</given-names></name><name><surname>Pogoda</surname><given-names>K</given-names></name><name><surname>Velikova</surname><given-names>G</given-names></name><name><surname>Bjelic-Radisic</surname><given-names>V</given-names></name><name><surname>Cardoso</surname><given-names>F</given-names></name><name><surname>Brain</surname><given-names>E</given-names></name><name><surname>Ignatiadis</surname><given-names>M</given-names></name></person-group><article-title>Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer</article-title><source>Eur J Cancer</source><year>2020</year><volume>125</volume><fpage>69</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2019.10.031</pub-id><pub-id pub-id-type="pmid">31838407</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Mierzynska J, Taye M, Pe M, Coens C, Martinelli F, Pogoda K, Velikova G, Bjelic-Radisic V, Cardoso F, Brain E, Ignatiadis M (2020) Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer. Eur J Cancer 125:69&#x02013;82. 10.1016/j.ejca.2019.10.031<pub-id pub-id-type="pmid">31838407</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>FM</given-names></name><name><surname>Tsai</surname><given-names>WL</given-names></name><name><surname>Chien</surname><given-names>CY</given-names></name><name><surname>Chiu</surname><given-names>HC</given-names></name><name><surname>Wang</surname><given-names>CJ</given-names></name><name><surname>Chen</surname><given-names>HC</given-names></name><name><surname>Hsiung</surname><given-names>CY</given-names></name></person-group><article-title>Changing quality of life in patients with advanced head and neck cancer after primary radiotherapy or chemoradiation</article-title><source>Oncology</source><year>2005</year><volume>68</volume><fpage>405</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1159/000086982</pub-id><pub-id pub-id-type="pmid">16020970</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Fang FM, Tsai WL, Chien CY, Chiu HC, Wang CJ, Chen HC, Hsiung CY (2005) Changing quality of life in patients with advanced head and neck cancer after primary radiotherapy or chemoradiation. Oncology 68:405&#x02013;413. 10.1159/000086982<pub-id pub-id-type="pmid">16020970</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Ramsey</surname><given-names>I</given-names></name><name><surname>de Rooij</surname><given-names>BH</given-names></name><name><surname>Mols</surname><given-names>F</given-names></name><name><surname>Corsini</surname><given-names>N</given-names></name><name><surname>Horevoorts</surname><given-names>NJE</given-names></name><name><surname>Eckert</surname><given-names>M</given-names></name><name><surname>van de Poll-Franse</surname><given-names>LV</given-names></name></person-group><article-title>Cancer survivors who fully participate in the PROFILES registry have better health-related quality of life than those who drop out</article-title><source>J Cancer Surviv</source><year>2019</year><volume>13</volume><fpage>829</fpage><lpage>839</lpage><pub-id pub-id-type="doi">10.1007/s11764-019-00793-7</pub-id><pub-id pub-id-type="pmid">31493162</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Ramsey I, de Rooij BH, Mols F, Corsini N, Horevoorts NJE, Eckert M, van de Poll-Franse LV (2019) Cancer survivors who fully participate in the PROFILES registry have better health-related quality of life than those who drop out. J Cancer Surviv 13:829&#x02013;839. 10.1007/s11764-019-00793-7<pub-id pub-id-type="pmid">31493162</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Tripathy</surname><given-names>D</given-names></name><name><surname>Blum</surname><given-names>JL</given-names></name><name><surname>Rocque</surname><given-names>G</given-names></name><name><surname>Cuevas</surname><given-names>JD</given-names></name><name><surname>Specht</surname><given-names>J</given-names></name><name><surname>Corso</surname><given-names>S</given-names></name><name><surname>Francis</surname><given-names>JE</given-names></name><name><surname>Mendez</surname><given-names>S</given-names></name><name><surname>Pope</surname><given-names>V</given-names></name><name><surname>Cappelleri</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Impact of COVID-19 on study sites: survey analysis from the noninterventional POLARIS study</article-title><source>Cancer Res</source><year>2021</year><pub-id pub-id-type="doi">10.1158/1538-7445.Sabcs20-ss2-10</pub-id><pub-id pub-id-type="pmid">34518211</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Tripathy D, Blum JL, Rocque G, Cuevas JD, Specht J, Corso S, Francis JE, Mendez S, Pope V, Cappelleri J, Wang Y (2021) Impact of COVID-19 on study sites: survey analysis from the noninterventional POLARIS study. Cancer Res. 10.1158/1538-7445.Sabcs20-ss2-10<pub-id pub-id-type="pmid">34518211</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Finn</surname><given-names>RS</given-names></name><name><surname>Martin</surname><given-names>M</given-names></name><name><surname>Rugo</surname><given-names>HS</given-names></name><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Im</surname><given-names>SA</given-names></name><name><surname>Gelmon</surname><given-names>K</given-names></name><name><surname>Harbeck</surname><given-names>N</given-names></name><name><surname>Lipatov</surname><given-names>ON</given-names></name><name><surname>Walshe</surname><given-names>JM</given-names></name><name><surname>Moulder</surname><given-names>S</given-names></name><name><surname>Gauthier</surname><given-names>E</given-names></name><name><surname>Lu</surname><given-names>DR</given-names></name><name><surname>Randolph</surname><given-names>S</given-names></name><name><surname>Di&#x000e9;ras</surname><given-names>V</given-names></name><name><surname>Slamon</surname><given-names>DJ</given-names></name></person-group><article-title>Palbociclib and letrozole in advanced breast cancer</article-title><source>N Engl J Med</source><year>2016</year><volume>375</volume><fpage>1925</fpage><lpage>1936</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1607303</pub-id><pub-id pub-id-type="pmid">27959613</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Di&#x000e9;ras V, Slamon DJ (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375:1925&#x02013;1936. 10.1056/NEJMoa1607303<pub-id pub-id-type="pmid">27959613</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>NC</given-names></name><name><surname>Ro</surname><given-names>J</given-names></name><name><surname>Andr&#x000e9;</surname><given-names>F</given-names></name><name><surname>Loi</surname><given-names>S</given-names></name><name><surname>Verma</surname><given-names>S</given-names></name><name><surname>Iwata</surname><given-names>H</given-names></name><name><surname>Harbeck</surname><given-names>N</given-names></name><name><surname>Loibl</surname><given-names>S</given-names></name><name><surname>Huang Bartlett</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Giorgetti</surname><given-names>C</given-names></name><name><surname>Randolph</surname><given-names>S</given-names></name><name><surname>Koehler</surname><given-names>M</given-names></name><name><surname>Cristofanilli</surname><given-names>M</given-names></name></person-group><article-title>Palbociclib in hormone-receptor-positive advanced breast cancer</article-title><source>N Engl J Med</source><year>2015</year><volume>373</volume><fpage>209</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1505270</pub-id><pub-id pub-id-type="pmid">26030518</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Turner NC, Ro J, Andr&#x000e9; F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M (2015) Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 373:209&#x02013;219. 10.1056/NEJMoa1505270<pub-id pub-id-type="pmid">26030518</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>